Listed medicinal cannabis company Zelda Therapeutics (ASX: ZLD) has made progress in a number of key research programs during the March 2018 financial quarter. Zelda recently received approval for a major study into the pharmacology of cannabinoids in the treatment of paediatric autism patients.
read more here
Delivered by @can_nab_is
No comments:
Post a Comment